Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFaron Pharmaceuticals Share News (FARN)

Share Price Information for Faron Pharmaceuticals (FARN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 185.00
Bid: 180.00
Ask: 190.00
Change: 7.50 (4.23%)
Spread: 10.00 (5.556%)
Open: 177.50
High: 185.00
Low: 177.50
Prev. Close: 177.50
FARN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: Microsaic completes acquisition; Narf revenue soars

Thu, 25th Jan 2024 20:09

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

----------

Kavango Resources PLC - Southern Africa-focused metals explorer - Prepares to commence drilling a fourth prospect at the Hillside Gold Project in Zimbabwe. Target depth is 250m to test a number of possible gold-bearing structures. Results aim to inform possible follow-up drilling, targeting a bulk-mineable gold discovery. Chief Executive Ben Turney says: "There is enormous, unrealised potential in the goldfields of Zimbabwe."

----------

Hummingbird Resources PLC - West Africa-focused and Birmingham, England-based gold producer, developer and explorer - Provides an update on operations at its Kouroussa Gold Mine. Reports mining operations at Kouroussa are restarting shortly and are expected to ramp up to full capacity levels over the coming weeks. This follows temporary suspension due to a fire. Remains focused on reaching full commercial production in the first quarter.

----------

Faron Pharmaceuticals Ltd - Turku, Finland-based clinical-stage biopharmaceutical company specialising in cancer therapies - Reports patients are currently being enrolled in the Phase 2 of the Bexmab trial, which is evaluating the safety and efficacy of investigational immunotherapy bexmarilimab at two dose levels. In the meantime, further analysis of Phase 1 showed a 100% overall response rate achieved among both the higher-risk frontline and HMA-failed myelodysplastic syndrome patients treated with a bexmarilimab/azacitidine combination.

----------

NARF Industries PLC - London-based cybersecurity group which specialises in high-end threat intelligence and critical infrastructure security - Reports that revenue more than doubles to USD6.0 million in 2023 from USD2.5 million. Swings to positive earnings before interest, tax, depreciation and amortisation, from a USD2.6 million loss in 2022.

----------

Microsaic Systems PLC - Surrey-based developer of real-time mass spectrometers - Completes the GBP100,000 acquisition of the modern water assets and the Microtox water testing business previously owned by DeepVerge PLC. Deal was announced on January 12.

----------

By Jeremy Cutler, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights Reserved.

More News

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.